Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Supraclavicular lymph nodes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Supraclavicular lymph nodes. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-005219-98 Sponsor Protocol Number: PH3-01 Start Date*: 2012-10-08
    Sponsor Name:Galena Biopharma, Inc
    Full Title: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)
    Medical condition: Operable early-stage, node-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10071113 Node-positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002425-52 Sponsor Protocol Number: H3E-MC-JMEN(a) Start Date*: 2005-03-24
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 3 Study of Pemetrexed Plus Best Supportive Care versus Best Supportive Care As Maintenance Therapy Immediately Following Induction Treatment For Advanced Non-Small Cell Lung Cancer
    Medical condition: Non Small Cell Lung Cancer Stage IIIB or Stage IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000251-18 Sponsor Protocol Number: PO4572 Start Date*: 2006-05-12
    Sponsor Name:Dr. Llombart Cussac
    Full Title: Phase II Cardiac Safety trial of liposomal pegillated doxorrubicine in patients with breast cancer with non evidence of disease and previous exposition to Antraciclines. Estudio Fase II de Seguri...
    Medical condition: Non evidence of disease (NED) Breast cancer.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004307-39 Sponsor Protocol Number: RG_13-090 Start Date*: 2015-01-08
    Sponsor Name:University of Birmingham
    Full Title: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neo-adjuvant 5-Fluorouracil, Epirubicin and Cyclophospham...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-002155-24 Sponsor Protocol Number: H3E-EW-S124 Start Date*: 2008-08-06
    Sponsor Name:Eli Lilly and Company Limited, UK
    Full Title: A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplat...
    Medical condition: Advanced Non-Squamous Non Small Cell Lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025055 Lung cancer non-small cell stage IV LLT
    9.1 10025054 Lung cancer non-small cell stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) PT (Completed) ES (Completed) DE (Completed) FR (Completed) FI (Completed) BE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002665-30 Sponsor Protocol Number: RENAISSANCE Start Date*: 2016-01-11
    Sponsor Name:Krankenhaus Nordwest gGmbH
    Full Title: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric jun...
    Medical condition: limited-metastatic adenocarcinoma of the stomach or esophagogastric junction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001484-64 Sponsor Protocol Number: IBCSG 27-02/BIG 1-02/GEICAM 2002/04 Start Date*: 2006-04-06
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: Chemotherapy for Radically Resected Loco-regional Relapse A randomized clinical trial of adjuvant chemotherapy for radically resected loco-regional relapse of breast cancer Chemotherapy vs. Observa...
    Medical condition: Patients with radically treated isolated local and/or regional recurrence of invasive breast cancer after mastectomy or breast-conserving surgery.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000394-23 Sponsor Protocol Number: SOLTI-1007 Start Date*: 2012-08-06
    Sponsor Name:SOLTI
    Full Title: A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN®) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer
    Medical condition: Patients at Stage I-II HER2-negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000744-17 Sponsor Protocol Number: LONG 05-05 Start Date*: 2006-03-22
    Sponsor Name:University Hospital Ghent
    Full Title: A randomised phase II study evaluating two schedules of the 21-day regimen of Gemcitabine and Carboplatin in advanced NSCLC
    Medical condition: Non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001283-73 Sponsor Protocol Number: 109493 Start Date*: 2007-08-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable ...
    Medical condition: Adjuvant therapy in patients with MAGE-A3-positive Non-Small Cell Lung Cancer (NSCLC) and who have had complete surgical resection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029517 Non-small cell lung cancer stage I PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) IE (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) SI (Prematurely Ended) FR (Completed) SE (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) AT (Completed) NL (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005858-23 Sponsor Protocol Number: PROMIX Start Date*: 2008-03-12
    Sponsor Name:PROMIX Trial Group
    Full Title: Preoperative treatment of breast cancer with a combination of epirubicin, docetaxel and bevacizumab. A translational trial on molecular markers and functional imaging to predict response early
    Medical condition: Patients diagnosed with breast cancer who are candidates for preoperative (neoadjuvant) chemotherapy due to localized primary breast cancer including inflammatory breast cancer suitable for primary...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006200 Breast cancer stage II LLT
    9.1 10006201 Breast cancer stage III LLT
    9.1 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003605-55 Sponsor Protocol Number: 74556 Start Date*: 2021-01-15
    Sponsor Name:Erasmus MC - University Medical Centre
    Full Title: Combination of chemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and gastro-oesophageal junction with oligometastatic disease
    Medical condition: Patients (18 – 75 years) who are diagnosed with adenocarcinoma of the oesophagus or GOJ with a resectable primary tumour and de-novo synchronous oligometastatic disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004035-24 Sponsor Protocol Number: I3Y-MC-JPCW Start Date*: 2021-04-26
    Sponsor Name:Eli Lilly and Company
    Full Title: eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Brea...
    Medical condition: High-Risk, Node-Positive, HR+, HER2+ Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) FI (Prematurely Ended) AT (Completed) HU (Completed) GR (Completed) IT (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000129-28 Sponsor Protocol Number: GO42784 Start Date*: 2021-08-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WIT...
    Medical condition: Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) SK (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) SI (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001370-88 Sponsor Protocol Number: IBCSG 35-07/ BIG 1-07 Start Date*: 2007-11-06
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor...
    Medical condition: Postmenopausal women who are disease-free following 4-6 years of prior adjuvant endocrine therapy with selective estrogen receptor modulator(s) (SERM) and/or aromatase inhibitor(s) (AI) for endocri...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) BE (Completed) HU (Completed) IT (Completed) DE (Completed) DK (Completed) GB (Completed) ES (Completed) SI (Completed) GR (Completed) AT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002597-44 Sponsor Protocol Number: CFZ004 Start Date*: 2014-02-10
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer
    Medical condition: Untreated extensive stage small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006383-10 Sponsor Protocol Number: IEO S439/508 Start Date*: 2009-04-28
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A phase II randomized study evaluating the role of 8 courses of primary chemotherapy versus 4 courses of primary chemotherapy in combination with endocrine therapy in locally advanced breast c...
    Medical condition: locally advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004022-36 Sponsor Protocol Number: CCR5316 Start Date*: 2022-01-07
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus fulvestrant versus standard endocrine therapy in patients with ER...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015238-31 Sponsor Protocol Number: M09TNM Start Date*: 2009-12-16
    Sponsor Name:NKI-AVL
    Full Title: RANDOMIZED PHASE II/III STUDY OF INDIVIDUALIZED NEOADJUVANT CHEMOTHERAPY IN ‘TRIPLE-NEGATIVE’ BREAST TUMORS
    Medical condition: Triple negative breast cancer treated with neoadjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005051-42 Sponsor Protocol Number: PR016-CLN-pro003 Start Date*: 2008-03-20
    Sponsor Name:Protherics Salt Lake City, Inc
    Full Title: A randomized study of the efficacy and safety of OncoGel™ treatment as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation prior to surgery in subjects with locali...
    Medical condition: localized or loco-regional esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:43:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA